Literature DB >> 27227723

Doubly Robust and Efficient Estimation of Marginal Structural Models for the Hazard Function.

Wenjing Zheng, Maya Petersen, Mark J van der Laan.   

Abstract

In social and health sciences, many research questions involve understanding the causal effect of a longitudinal treatment on mortality (or time-to-event outcomes in general). Often, treatment status may change in response to past covariates that are risk factors for mortality, and in turn, treatment status may also affect such subsequent covariates. In these situations, Marginal Structural Models (MSMs), introduced by Robins (1997. Marginal structural models Proceedings of the American Statistical Association. Section on Bayesian Statistical Science, 1-10), are well-established and widely used tools to account for time-varying confounding. In particular, a MSM can be used to specify the intervention-specific counterfactual hazard function, i. e. the hazard for the outcome of a subject in an ideal experiment where he/she was assigned to follow a given intervention on their treatment variables. The parameters of this hazard MSM are traditionally estimated using the Inverse Probability Weighted estimation Robins (1999. Marginal structural models versus structural nested models as tools for causal inference. In: Statistical models in epidemiology: the environment and clinical trials. Springer-Verlag, 1999:95-134), Robins et al. (2000), (IPTW, van der Laan and Petersen (2007. Causal effect models for realistic individualized treatment and intention to treat rules. Int J Biostat 2007;3:Article 3), Robins et al. (2008. Estimaton and extrapolation of optimal treatment and testing strategies. Statistics in Medicine 2008;27(23):4678-721)). This estimator is easy to implement and admits Wald-type confidence intervals. However, its consistency hinges on the correct specification of the treatment allocation probabilities, and the estimates are generally sensitive to large treatment weights (especially in the presence of strong confounding), which are difficult to stabilize for dynamic treatment regimes. In this paper, we present a pooled targeted maximum likelihood estimator (TMLE, van der Laan and Rubin (2006. Targeted maximum likelihood learning. The International Journal of Biostatistics 2006;2:1-40)) for MSM for the hazard function under longitudinal dynamic treatment regimes. The proposed estimator is semiparametric efficient and doubly robust, offering bias reduction over the incumbent IPTW estimator when treatment probabilities may be misspecified. Moreover, the substitution principle rooted in the TMLE potentially mitigates the sensitivity to large treatment weights in IPTW. We compare the performance of the proposed estimator with the IPTW and a on-targeted substitution estimator in a simulation study.

Entities:  

Mesh:

Year:  2016        PMID: 27227723      PMCID: PMC4912008          DOI: 10.1515/ijb-2015-0036

Source DB:  PubMed          Journal:  Int J Biostat        ISSN: 1557-4679            Impact factor:   0.968


  17 in total

1.  Using inverse weighting and predictive inference to estimate the effects of time-varying treatments on the discrete-time hazard.

Authors:  Ree Dawson; Philip W Lavori
Journal:  Stat Med       Date:  2002-06-30       Impact factor: 2.373

2.  When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data.

Authors:  Lauren E Cain; James M Robins; Emilie Lanoy; Roger Logan; Dominique Costagliola; Miguel A Hernán
Journal:  Int J Biostat       Date:  2010       Impact factor: 0.968

3.  Doubly robust estimation in missing data and causal inference models.

Authors:  Heejung Bang; James M Robins
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

4.  Intervening on risk factors for coronary heart disease: an application of the parametric g-formula.

Authors:  Sarah L Taubman; James M Robins; Murray A Mittleman; Miguel A Hernán
Journal:  Int J Epidemiol       Date:  2009-04-23       Impact factor: 7.196

5.  Estimation and extrapolation of optimal treatment and testing strategies.

Authors:  James Robins; Liliana Orellana; Andrea Rotnitzky
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

6.  Causal effect models for realistic individualized treatment and intention to treat rules.

Authors:  Mark J van der Laan; Maya L Petersen
Journal:  Int J Biostat       Date:  2007       Impact factor: 0.968

7.  Targeted minimum loss based estimation of causal effects of multiple time point interventions.

Authors:  Mark J van der Laan; Susan Gruber
Journal:  Int J Biostat       Date:  2012       Impact factor: 0.968

8.  A targeted maximum likelihood estimator of a causal effect on a bounded continuous outcome.

Authors:  Susan Gruber; Mark J van der Laan
Journal:  Int J Biostat       Date:  2010-08-01       Impact factor: 0.968

9.  Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification.

Authors:  Maya L Petersen; Mark J van der Laan; Sonia Napravnik; Joseph J Eron; Richard D Moore; Steven G Deeks
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

10.  When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

Authors:  Lauren E Cain; Roger Logan; James M Robins; Jonathan A C Sterne; Caroline Sabin; Loveleen Bansi; Amy Justice; Joseph Goulet; Ard van Sighem; Frank de Wolf; Heiner C Bucher; Viktor von Wyl; Anna Esteve; Jordi Casabona; Julia del Amo; Santiago Moreno; Remonie Seng; Laurence Meyer; Santiago Perez-Hoyos; Roberto Muga; Sara Lodi; Emilie Lanoy; Dominique Costagliola; Miguel A Hernan
Journal:  Ann Intern Med       Date:  2011-04-19       Impact factor: 25.391

View more
  1 in total

1.  Risk factors associated with sexually transmitted infections among HIV infected men who have sex with men.

Authors:  Yun Xian; Bowen Zhu; Xuan Zhang; Ping Ma; Ye Wei; Hongli Xia; Wenjie Jiang; Changqing Yang; Xiaojun Meng; Peng Peng; Yue Yang; Liying Jiang; Minjie Chu; Xun Zhuang
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.